Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOX
19 January 2011 | By Merck KGaA
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUSa study...